European Medicines Agency recommends suspension of marketing authorisations for sibutramine (EMA Press release, 21 January 2010)

22 Jan 2010

The European Medicines Agency has released a press release recommending the Europe-wide suspension of the anti-obesity drug sibutramine. The recommendation follows findings from a 6-year trial that linked the drug with an increased risk of non-fatal heart attack and stroke.